Key result
Withaferin-A and Baicalin demonstrated high binding affinities of -10.7 kcal/mol and -9.5 kcal/mol, respectively, to the EV-D68 3C protease in computational simulations.
Why the study?
Enterovirus D68 causes severe respiratory and neurological complications with no FDA-approved antiviral treatments currently available, making its essential 3C protease a key therapeutic target.
Computational screening identified Withaferin-A and Baicalin as potential natural inhibitors of the EV-D68 3C protease, providing candidates for future experimental validation.
Answers are grounded in this paper and cite their sources.
Computational hits suggest EV-D68 3C protease inhibitors; leaves open experimental validation before any therapeutic consideration.
Enterovirus D68 (EV-D68) is a significant global health threat, responsible for severe respiratory and neurological complications, with no FDA-approved antiviral treatments currently available. The 3C protease of EV-D68, an essential enzyme involved in viral replication, represents a key target for therapeutic development. In this study, we employed a comprehensive computational approach, including molecular docking, pharmacokinetic predictions, and molecular dynamics simulations, to identify potential natural inhibitors of the EV-D68 3C protease. Screening a library of natural compounds, Withaferin-A (CID: 265,237) and Baicalin (CID: 64,982) emerged as top candidates due to their favorable pharmacokinetic profiles, high binding affinities (-10.7 kcal/mol for Withaferin-A and -9.5 kcal/mol for Baicalin), and interactions with key residues in the protease's active site. The molecular dynamics simulations demonstrated the stability of the protein-ligand complexes, with low root mean square deviation (RMSD) and fluctuation (RMSF) values over a 100-ns trajectory. Free energy calculations further supported the superior binding efficiency of Withaferin-A. These findings suggest that Withaferin-A and Baicalin have significant potential as natural inhibitors of EV-D68 3C protease, offering a promising foundation for future experimental validation and the development of targeted antiviral therapies against EV-D68.
No takes yet. Share an insight, caveat, or question.
Mansoor Alsahag (2025) studied Enterovirus D68 (EV-D68) infection. Withaferin-A and Baicalin was evaluated on Binding affinity to EV-D68 3C protease (-10.7 kcal/mol (Withaferin-A) and -9.5 kcal/mol (Baicalin)). Withaferin-A and Baicalin demonstrated high binding affinities of -10.7 kcal/mol and -9.5 kcal/mol, respectively, to the EV-D68 3C protease in computational simulations.
Synapse has enriched 10 related papers. Consider them for comparative context: